RLMD
Relmada Therapeutics Inc.
$6.97
+$0.21(+3.19%)
61
Overall
60
Value
63
Tech
--
Quality
Market Cap
$50.78M
Volume
458.55K
52W Range
$0.24 - $7.51
Target Price
$12.80
Company Overview
| Mkt Cap | $50.78M | Price | $6.97 |
| Volume | 458.55K | Change | +3.19% |
| P/E Ratio | -0.6 | Open | $6.93 |
| Revenue | -- | Prev Close | $6.75 |
| Net Income | $-80.0M | 52W Range | $0.24 - $7.51 |
| Div Yield | N/A | Target | $12.80 |
| Overall | 61 | Value | 60 |
| Quality | -- | Technical | 63 |
No chart data available
About Relmada Therapeutics Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest News
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)
TipRanks Auto-Generated Intelligence Newsdesk•20 hours ago
Relmada Therapeutics Charts Aggressive Path After Earnings Call
TipRanks Auto-Generated Newsdesk•19 days ago
Relmada Highlights NDV-01 Data, Funding in 2025 Results
TipRanks Auto-Generated Newsdesk•19 days ago
Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors
TipRanks Clinical-Trials-Auto-Generated Newsdesk•22 days ago
Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors
TipRanks Clinical-Trials-Auto-Generated Newsdesk•22 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RLMD | $6.97 | +3.2% | 458.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Relmada Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW